Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss
after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year